Tags

Type your tag names separated by a space and hit enter

COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy.
Stem Cell Rev Rep. 2021 02; 17(1):113-131.SC

Abstract

The novel virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) caused the Corona Virus Disease-2019 (COVID-19) outbreak in Wuhan, Hubei province of China. This virus disseminated rapidly and reached to an unprecedented pandemic proportion in more than 213 nations with a large number of fatalities. The hypersecretion of pro-inflammatory cytokines is the main cause of mortality and morbidity due to COVID-19, therefore strategies that avert the cytokine storm may play a crucial role in abating the severity of COVID-19. This review highlights the minute details of SARS-CoV-2, its genomic organization, genomic variations within structural and non-structural proteins and viral progression mechanism in human beings. The approaches like antiviral strategies are discussed, including drugs that obstruct viral propagation and suppress the pro-inflammatory cytokines. This compilation emphasizes Mesenchymal Stem Cells (MSCs) based therapy alone or in combination with other therapeutics as an attractive curative approach for COVID-19 pandemic. The MSCs and its secretome, including antimicrobial peptides (AMPs) have various capabilities, for instance, immunomodulation, regeneration, antimicrobial properties, potential for attenuating the cytokine storm and bare minimum chances of being infected with SARS-CoV-2 virus. The immunomodulatory property of MSCs affects inflammatory state and regulates immune response during SARS-CoV-2 infection. However, as of now, there is no WHO-approved MSCs based therapy for the treatment of COVID-19 infection. Graphical abstract.

Authors+Show Affiliations

Division of Stem Cell & Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences (INMAS), Brig. S.K. Mazumdar Road, Delhi, 110054, India.Division of Stem Cell & Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences (INMAS), Brig. S.K. Mazumdar Road, Delhi, 110054, India.Division of Stem Cell & Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences (INMAS), Brig. S.K. Mazumdar Road, Delhi, 110054, India.Division of Stem Cell & Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences (INMAS), Brig. S.K. Mazumdar Road, Delhi, 110054, India.Division of Stem Cell & Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences (INMAS), Brig. S.K. Mazumdar Road, Delhi, 110054, India.Division of Stem Cell & Gene Therapy Research, Institute of Nuclear Medicine & Allied Sciences (INMAS), Brig. S.K. Mazumdar Road, Delhi, 110054, India. gugdutta@rediffmail.com.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32920752

Citation

Verma, Yogesh Kumar, et al. "COVID-19 and Its Therapeutics: Special Emphasis On Mesenchymal Stem Cells Based Therapy." Stem Cell Reviews and Reports, vol. 17, no. 1, 2021, pp. 113-131.
Verma YK, Verma R, Tyagi N, et al. COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. Stem Cell Rev Rep. 2021;17(1):113-131.
Verma, Y. K., Verma, R., Tyagi, N., Behl, A., Kumar, S., & Gangenahalli, G. U. (2021). COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. Stem Cell Reviews and Reports, 17(1), 113-131. https://doi.org/10.1007/s12015-020-10037-2
Verma YK, et al. COVID-19 and Its Therapeutics: Special Emphasis On Mesenchymal Stem Cells Based Therapy. Stem Cell Rev Rep. 2021;17(1):113-131. PubMed PMID: 32920752.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem Cells Based Therapy. AU - Verma,Yogesh Kumar, AU - Verma,Ranjan, AU - Tyagi,Nishant, AU - Behl,Amanpreet, AU - Kumar,Subodh, AU - Gangenahalli,Gurudutta U, PY - 2020/9/14/pubmed PY - 2021/3/3/medline PY - 2020/9/13/entrez KW - Antimicrobial peptides KW - Cytokine storm KW - MSCs transplantation KW - Repurposed drugs KW - SARS-CoV-2 SP - 113 EP - 131 JF - Stem cell reviews and reports JO - Stem Cell Rev Rep VL - 17 IS - 1 N2 - The novel virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) caused the Corona Virus Disease-2019 (COVID-19) outbreak in Wuhan, Hubei province of China. This virus disseminated rapidly and reached to an unprecedented pandemic proportion in more than 213 nations with a large number of fatalities. The hypersecretion of pro-inflammatory cytokines is the main cause of mortality and morbidity due to COVID-19, therefore strategies that avert the cytokine storm may play a crucial role in abating the severity of COVID-19. This review highlights the minute details of SARS-CoV-2, its genomic organization, genomic variations within structural and non-structural proteins and viral progression mechanism in human beings. The approaches like antiviral strategies are discussed, including drugs that obstruct viral propagation and suppress the pro-inflammatory cytokines. This compilation emphasizes Mesenchymal Stem Cells (MSCs) based therapy alone or in combination with other therapeutics as an attractive curative approach for COVID-19 pandemic. The MSCs and its secretome, including antimicrobial peptides (AMPs) have various capabilities, for instance, immunomodulation, regeneration, antimicrobial properties, potential for attenuating the cytokine storm and bare minimum chances of being infected with SARS-CoV-2 virus. The immunomodulatory property of MSCs affects inflammatory state and regulates immune response during SARS-CoV-2 infection. However, as of now, there is no WHO-approved MSCs based therapy for the treatment of COVID-19 infection. Graphical abstract. SN - 2629-3277 UR - https://www.unboundmedicine.com/medline/citation/32920752/COVID_19_and_its_Therapeutics:_Special_Emphasis_on_Mesenchymal_Stem_Cells_Based_Therapy_ DB - PRIME DP - Unbound Medicine ER -